Insider buying last 90 days
No open-market insider purchases were filed for NKTR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NKTR insider filing, plotted on the chart in Gekko.Open NKTR in Gekko
NASDAQ: NKTR
Nektar Therapeutics (NKTR) Stock Analysis & Forecast
Oct 12 close
$39.84−1.33 (−3.2%)
Gekko Brief
AI summaryOct 12 closeNektar Therapeutics shares moved this week on a mix of legal, analyst and clinical news. The company secured a $115 million lawsuit victory over Eli Lilly resolving a contract dispute, which BTIG cited alongside expectations of a further $130 million-$140 million legal award in reiterating its Buy rating with a $178 price target. Raymond James initiated coverage at Market Perform. Separately, long-term Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis were highlighted as supportive of Phase 3 plans, and reporting noted a projected cash balance of $815 million to $840 million by year-end 2026, providing runway into 2028.
The stock closed at $39.84, down 3.2% on the day, and sits well below both its 50-day average of $65.85 and 200-day average of $65.27, with one-month, three-month and six-month returns all sharply negative. The GekkoIndex reads 72.2, placing NKTR in the Buying zone, while price stands 54.1% below Gekko Fair Value of $86.78.
Looking ahead, earnings are due 5 November, 23 days out and within a typical 20-trading-day holding window, following a prior quarter where actual EPS of -1.23 beat the estimate of -2.06 with a -4% reaction. No insider, Congress or unusual options activity appears in the current windows. Seasonality for this calendar stretch has averaged +0.7% over 5 years, rising in 4 of them, worth noting alongside the single trailblazer holder on record.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Nektar Therapeutics price vs fair value
Close $39.84200-day averageGekko Fair Value $86.78
Nektar Therapeutics quick facts
- Market cap
- $1.14B
- P/E ratio
- —
- Forward P/E
- 34
- EPS, TTM
- −$18.96
- Revenue, TTM
- $54.59M
- Profit margin
- -287.8%
- Dividend yield
- —
- Beta
- 1.27
- Volume
- 954,984 avg 1.86M
- 1-year return
- −28.4%
- Typical daily move
- ±10.1%
- Typical 20-day move
- ±15.6%
- 50-day average
- $65.85
- 200-day average
- $65.27
- Next earnings
- Nov 5 after close
- Shares outstanding
- 34.14M
Nektar Therapeutics swing-trade checklist
Nektar Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $39.84 sits between the 50-day ($65.85) and 200-day ($65.27) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
72.2, Buying
Reading 72.2 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
54.1% below
Price is 54.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+0.7% on average
From this point in the calendar, the next 20 trading days averaged +0.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Nektar Therapeutics stock chart and price history
Nektar Therapeutics closed at $39.84 on Oct 12, 2026, −28.4% over the past year, inside a 52-week range of $33.40 to $109.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −42.9%
- 3 months
- −40.7%
- 6 months
- −50.5%
- 1 year
- −28.4%
The full NKTR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NKTR in Gekko
Follow Nektar Therapeutics through every session
Put NKTR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NKTR in GekkoFree for 7 days. No credit card required.
About Nektar Therapeutics
Nektar Therapeutics works on discovering and developing new medicines aimed at health conditions that still lack adequate treatment options worldwide. The company is best recognized for Bempegaldesleukin, a compound that acts on the interleukin-2 pathway and is being tested in late-stage trials against cancers including metastatic melanoma, renal cell carcinoma, bladder cancer, and head and neck cancer, alongside earlier-stage studies in lung and urothelial cancers and even COVID-19. Its broader pipeline includes additional experimental drugs such as NKTR-358, NKTR-255, and NKTR-262, targeting conditions ranging from lupus and ulcerative colitis to lymphoma, myeloma, and solid tumors.
Much of this research moves forward through partnerships rather than solo development. Nektar Therapeutics has collaboration agreements with a wide range of pharmaceutical companies, among them Takeda, AstraZeneca, UCB, Roche, Bausch Health, Pfizer, Amgen, Bristol-Myers Squibb, Baxalta, Eli Lilly, Merck KGaA, and SFJ Pharmaceuticals, reflecting a model built on shared drug development efforts across the industry.
Founded in 1990, the company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ under the ticker NKTR.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- nektar.com
Nektar Therapeutics GekkoIndex: the smart money zone
Nektar Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 72.2, in the Buying zone, down 9.8 points over five sessions.
72.2Buying
Down 9.8 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 48 | +1.9% | +11.7% | ||
| Accumulation | 196 | +6.5% | +19.7% | ||
| Neutral | 382 | +1.3% | +7.4% | ||
| Distribution | 51 | +1.5% | +11.0% | ||
| Selling | 5 | Too few readings yet | |||
Average NKTR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the NKTR price, zone by zone.Track NKTR in Gekko
Is Nektar Therapeutics stock overvalued? Gekko Fair Value
Nektar Therapeutics trades 54.1% below Gekko Fair Value of $86.78, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Nektar Therapeutics shares are worth, recalculated every trading day.
$86.78
Gekko Fair Value, Oct 10, 2026
54.1% Undervalued
At the end of Aug 2026 the price was 39.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NKTR in Gekko
Nektar Therapeutics insider and Congress trading
No open-market insider purchases were filed for Nektar Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NKTR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NKTR, plotted on the chart in Gekko.Open NKTR in Gekko
Buybacks
Nektar Therapeutics has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2024
- $3.00M
- As a share of market cap
- 0.26%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds NKTR.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Nektar Therapeutics earnings: next date and track record
Nektar Therapeutics reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- −$2.08
- Revenue estimate
- $10.31M
5 of 8reports beat the EPS estimate
±2.2%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 13, 2026 AI summary
- What they said
- Nektar Therapeutics' earnings call focused on clinical and regulatory progress for rezpeg (aldesleukin prodrug) and financial results/guidance. Management announced initiation of the global Zenith AD Phase 3 program for atopic dermatitis and finalized a single registrational Phase 3 design for alopecia areata (AA) to begin in early 2027. Topline data for the AD Phase 3 studies are expected mid-2028, with a potential BLA submission in 2029 if results are positive. Management highlighted rezpeg's novel Treg-agonist mechanism, durable responses in prior studies (including off-treatment durability), and plans to explore additional indications including type 1 diabetes (TrialNet Phase 2) and TNFR2 agonist antibody programs (NKTR-0165/0166). Financially, the company reported Q2 results with $1.02 billion in cash and investments at quarter-end, completed a $350 million offering in April, and provided updated year-end 2026 cash guidance of approximately $815 million to $840 million. Full-year 2026 revenue is expected to be $40–45 million; R&D expense $210–230 million; G&A $60–65 million; noncash interest $30–35 million. Q2 net loss was $40.6 million ($1.23 per share). Management emphasized the large market opportunity in AD and AA, confidence in trial design, and a favorable safety/dosing profile for rezpeg.
- Guidance
- Updated year-end 2026 cash and investments: approximately $815 million to $840 million. Full-year 2026 revenue: $40 million to $45 million. Full-year 2026 R&D expense: $210 million to $230 million (includes ~$5–10M noncash). Full-year 2026 G&A expense: $60 million to $65 million (includes ~$5M noncash). Noncash interest expense for 2026: approximately $30 million to $35 million. Expect R&D expense to increase quarterly as Phase 3 and CMC progress.
- Risks flagged
- Ongoing litigation (federal jury trial in San Francisco scheduled for September) with limited comment from management; typical biopharma development risks including clinical trial outcomes, regulatory review uncertainty, competition (other mechanisms and new entrants), enrollment/timing risks, and reliance on future positive Phase 3 results for registration and commercialization. Forward-looking statements subject to uncertainty and SEC-filed risk disclosures.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 13, 2026 | −$1.23 est −$2.06 | $10.13M est $10.43M | −4.0% |
| May 7, 2026 | −$1.82 est −$1.56 | $10.86M est $10.69M | −3.8% |
| Mar 12, 2026 | −$1.29 est −$3.49 | $21.81M est $10.19M | −0.1% |
| Nov 6, 2025 | −$1.85 est −$2.85 | $11.79M est $10.44M | +3.2% |
| Aug 7, 2025 | −$2.95 est −$3.13 | $11.18M est $9.42M | +2.7% |
| May 8, 2025 | −$3.61 est −$2.82 | $10.46M est $15.36M | −2.8% |
| Mar 12, 2025 | −$0.15 est −$0.13 | $29.18M est $36.66M | −0.5% |
| Nov 7, 2024 | −$0.18 est −$0.21 | $24.12M est $31.39M | +0.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Nektar Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Nektar Therapeutics is $141.40, +254.9% from the last close, from 14 firms rating the stock in the last 90 days.
$141.40consensus 12-month target, +254.9% from the last close
Now $39.84Avg $141.40
Low $50High $192
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | UBS | $53 | +33.0% |
| Oct 12 | Leerink Partners | $130 | +226.3% |
| Oct 9 | BTIG | $178 | +346.8% |
| Oct 8 | Raymond James | — | — |
| Oct 8 | Raymond James | — | — |
+11.7%average 20-day move after past Buying readings
+0.7%average move over the next 20 trading days in the last 5 years
±10.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Nektar Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Nektar Therapeutics averaged +0.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.7% | 4 of 5 |
| Next 10 trading days | +0.5% | 3 of 5 |
| Next 15 trading days | +0.5% | 2 of 5 |
| Next 20 trading days | +0.7% | 4 of 5 |
| Next 30 trading days | −14.9% | 0 of 5 |
For scale, NKTR’s typical 20-trading-day move in either direction is about 15.6%.
Nektar Therapeutics market cap and key statistics
Nektar Therapeutics’s market cap is $1.14B and revenue of $54.59M over the last twelve months.
Valuation
- Market cap
- $1.14B
- Forward P/E
- 34
- EPS, TTM
- −$18.96
- Gekko Fair Value
- $86.78
Trading
- Volume
- 954,984
- Avg volume, 20 days
- 1.86M
- 52-week high
- $109.00
- 52-week low
- $33.40
- Shares outstanding
- 34.14M
Financials
- Revenue, TTM
- $54.59M
- Profit margin
- -287.8%
- Return on equity
- -35.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.27
- Typical daily move
- ±10.1%
- Typical 20-day move
- ±15.6%
Nektar Therapeutics stock news this week
Coverage of Nektar Therapeutics this week reads positive: 7 positive, 4 neutral and 0 negative headlines.
- BTIG reiterates Buy rating on Nektar Therapeutics, $178 price targetTradingView, Oct 9
- Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR)Simply Wall Street, Oct 9
- Raymond James Starts Nektar Therapeutics (NKTR) at Market PerformStreetInsider, Oct 8
- Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year OverhangYahoo Finance, Oct 8
- Nektar Therapeutics stock faces a cash runway into 2028AD HOC NEWS, Oct 8
- Is Nektar Therapeutics (NKTR) Cheap As Rezpegaldesleukin Data Supports Phase 3 Plans?Simply Wall Street, Oct 8
Nektar Therapeutics peers
Nektar Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Nektar Therapeutics stock FAQ
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $1.14B at the Oct 12, 2026 close of $39.84, with 34.14M shares outstanding.
What is the Nektar Therapeutics stock forecast?
The consensus analyst 12-month price target for Nektar Therapeutics is $141.40, +254.9% from the last close. Of the 14 firms that rated the stock in the last 90 days, 10 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Nektar Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Nektar Therapeutics is undervalued: the Oct 12, 2026 close of $39.84 is 54.1% below Gekko Fair Value of $86.78. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Nektar Therapeutics report earnings next?
Nektar Therapeutics is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of −$2.08 per share on revenue of $10.31M. Nektar Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 2.2% on average across the report.
What is Nektar Therapeutics’s 52-week high and low?
Nektar Therapeutics’s 52-week high is $109.00 and its 52-week low is $33.40; it closed at $39.84 on Oct 12, 2026, −28.4% over the past year. Over the last five years the shares peaked at $268.65 on Oct 13, 2021.
Is Nektar Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Nektar Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.